| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 08/11/2004 | CN1161115C Inclusion complex |
| 08/11/2004 | CN1161110C Oral delayed immediate release formulation and method of preparation therefor |
| 08/10/2004 | US6774136 Substituted 1 and 2 naphthol mannich bases |
| 08/10/2004 | US6774132 Spirooxindole derivatives that act as analgesics |
| 08/10/2004 | US6774127 Pyrazole and pyrazoline substituted compounds |
| 08/10/2004 | US6774121 Phospholipid prodrugs of anti-proliferative drugs |
| 08/10/2004 | US6774118 Therapeutic use of CIS-element decoys in vivo |
| 08/10/2004 | US6774106 Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI |
| 08/10/2004 | US6773916 Administering sub-immunological sized antigen-binding molecule (fc/fv fragments) |
| 08/10/2004 | US6773724 Improved solubility |
| 08/10/2004 | US6773716 Over-coated chewing gum formulations |
| 08/10/2004 | US6773708 Suppression of excessive th1 and stimulation of th2 cell mediated immune responses |
| 08/10/2004 | US6773701 Expression enhancer for protein synthesis inhibitory genes |
| 08/10/2004 | CA2290125C Method for the preparation of citalopram |
| 08/10/2004 | CA2255661C Antiangiogenic drug to treat cancer, arthritis and retinopathy |
| 08/10/2004 | CA2187024C Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them |
| 08/10/2004 | CA2149013C A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent |
| 08/10/2004 | CA2147759C Tilidin dihydrogen orthophosphate, method of preparing it and pharmaceutical preparations containing it |
| 08/09/2004 | CA2538147A1 Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical |
| 08/05/2004 | WO2004065607A1 Novel physiologically active substance rs-k3574 and process for producing the same |
| 08/05/2004 | WO2004065365A1 8-azaprostaglandin derivatives and medicinal uses thereof |
| 08/05/2004 | WO2004065355A1 Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
| 08/05/2004 | WO2004064912A1 An otorhinological delivery device |
| 08/05/2004 | WO2004064857A1 Drugs containing galectin 9 |
| 08/05/2004 | WO2004064842A1 Amide and ester matrix metalloproteinase inhibitors |
| 08/05/2004 | WO2004064835A1 Use of ion channel modulating agents for treating pain |
| 08/05/2004 | WO2004064832A2 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist |
| 08/05/2004 | WO2004064827A1 Use of porphyrin synthesis substances for carrying out phototherapy and for curing skin and articulation diseases |
| 08/05/2004 | WO2004064753A2 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 08/05/2004 | WO2004064728A2 Use of specific tetracycline compounds in therapy |
| 08/05/2004 | WO2004064717A2 Cop 1 for treatment of inflammatory bowel diseases |
| 08/05/2004 | WO2004064716A2 Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders |
| 08/05/2004 | WO2004054557A3 Treatment of mastalgia with 4-hydroxy tamoxifen |
| 08/05/2004 | WO2004043925A3 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| 08/05/2004 | WO2004029031A3 Therapeutic piperazine compounds |
| 08/05/2004 | WO2004022716A9 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 08/05/2004 | WO2004010974A3 Gelatin capsule exhibiting reduced cross-linking |
| 08/05/2004 | WO2004010973A3 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 08/05/2004 | WO2004000226A3 Liposomes containing biologically active compounds |
| 08/05/2004 | WO2003103590A3 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| 08/05/2004 | WO2003048383A3 Effectors of innate immunity |
| 08/05/2004 | WO2003042359A3 Histamine receptor h3 polynucleotides |
| 08/05/2004 | WO2003029411A3 Novel cyclooxygenase variants and methods of use |
| 08/05/2004 | WO2003007689A3 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 08/05/2004 | US20040153126 Method and apparatus for treating uterine myoma |
| 08/05/2004 | US20040152906 Sulfonamides |
| 08/05/2004 | US20040152893 Sulfonamides |
| 08/05/2004 | US20040152891 Sulfonamides |
| 08/05/2004 | US20040152888 novel benzodiazepine derivatives |
| 08/05/2004 | US20040152785 Antiarthritic agents; bone disorders; oral diseases; nephritis; atherosclerosis; respiratory system disorders; cirrhosis; vision defects; anticancer agents; autoimmune diseases |
| 08/05/2004 | US20040152772 1-butyric acid derivatives and the use thereof |
| 08/05/2004 | US20040152768 NO-synthase inhibitors comprising ascorbyl 2-hexadecanoate |
| 08/05/2004 | US20040152761 Dimeric isoflavones |
| 08/05/2004 | US20040152754 Cyclic AMP-specific phosphodiesterase inhibitors |
| 08/05/2004 | US20040152753 Methods of use for novel sulfur containing organic nitrate compounds |
| 08/05/2004 | US20040152751 Viricides; suppress lymphocytes; aids therapy; antiinflammatory agents |
| 08/05/2004 | US20040152740 Central nervous system disorders; psychological disorders; analgesics |
| 08/05/2004 | US20040152738 Wound healing agents; antiarthritic agents; osteoporosis; congestive heart failure; antiulcer agents; Alzheimer's disease; anticholesterol agents; antiarthritic agents |
| 08/05/2004 | US20040152735 NO-synthase inhibitors comprising N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl) ethylenediamine |
| 08/05/2004 | US20040152734 Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds |
| 08/05/2004 | US20040152731 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivaties and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 08/05/2004 | US20040152730 Novel compounds |
| 08/05/2004 | US20040152726 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 08/05/2004 | US20040152725 Anticancer agents using a compound containing urea group |
| 08/05/2004 | US20040152723 Pharmaceutical compositions and methods for use |
| 08/05/2004 | US20040152713 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist |
| 08/05/2004 | US20040152705 Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives |
| 08/05/2004 | US20040152692 Pyrrolidine sulfonamides |
| 08/05/2004 | US20040152681 Interact with nuclear liver X receptor (LXR) and ubiquitous receptor (UR) and can be used to treat a variety of LXR- or UR-mediated disorders |
| 08/05/2004 | US20040152680 Treating autoimmune diseases, skin disorders, malignancies |
| 08/05/2004 | US20040152679 (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses |
| 08/05/2004 | US20040152678 Administering 20S)-1 alpha -hydroxy-2 alpha -methyl-19-nor-vitamin D3 for therapy of psoriasis |
| 08/05/2004 | US20040152677 (20S)-1alpha-hydroxy-2alpha-methl and 2beta-methyl-19-nor-vitamin D3 and their uses |
| 08/05/2004 | US20040152676 (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses |
| 08/05/2004 | US20040152675 (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses |
| 08/05/2004 | US20040152652 Therapy of inflammatory disorder in an individual comprising administering oligonucleotide up to 30 nucleotides in length complementary to a nucleic acid molecule encoding human tumor necrosis factor- alpha |
| 08/05/2004 | US20040152636 For therapy of diseases or disorders characterized by undesirable excessive vascularization such as tumors, rheumatoid arthritis, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, macular degeneration |
| 08/05/2004 | US20040152157 G-protein coupled receptors |
| 08/05/2004 | US20040152123 for drug screening enzyme inhibitors for cancer treatments; biochips; genetic engineering |
| 08/05/2004 | US20040152078 Genetic engineering |
| 08/05/2004 | US20040151938 Supplying to human or animals; into brain, tissues, lungs; coils, spring |
| 08/05/2004 | US20040151739 transporter and fusion protein contains a binding domain for the transporter and a modulation domain for the covalent modification of small GTP-binding proteins; transporter permits the uptake of the fusion protein in a target cell |
| 08/05/2004 | US20040151720 Cell surface molecule mediating cell adhesion and signal transmission |
| 08/05/2004 | US20040151669 Lymph cells detected by monoclonal antibodies; diagnosis of autoimmune disease, antiallergens |
| 08/05/2004 | DE10252666A1 N-Piperidyl-cyclohexan-Derivate N-piperidyl-cyclohexane derivatives |
| 08/05/2004 | CA2514108A1 Drugs containing galectin 9 |
| 08/05/2004 | CA2513432A1 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist |
| 08/05/2004 | CA2513115A1 Amide and ester matrix metalloproteinase inhibitors |
| 08/05/2004 | CA2512043A1 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 08/04/2004 | EP1442745A1 Orally administrable opioid formulations having extended duration of effect |
| 08/04/2004 | EP1442143A2 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/04/2004 | EP1442121A2 Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents |
| 08/04/2004 | EP1442061A1 Reducing immunogenicities of immunoglobulins by framework-patching |
| 08/04/2004 | EP1442058A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 08/04/2004 | EP1442050A2 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 08/04/2004 | EP1442049A2 Substituted amino ketone compounds |
| 08/04/2004 | EP1442046A2 Mammalian c-type lectins |
| 08/04/2004 | EP1442039A1 Pyrimido (4,5-b) indole derivatives |
| 08/04/2004 | EP1442036A2 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
| 08/04/2004 | EP1442034A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors |